{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-058973","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.900741+00:00","generated_at":"2026-05-23T04:58:20.790641+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Jaguar Health to discuss initial crofelemer POC results for MVID and SBS-IF on April 30 webcast","bullets":["Data presented April 26 at ELITE PED-GI Congress by Dr. Mohamad Miqdady.","No approved drug treatments for MVID, an ultrarare pediatric disease.","Webcast on April 30, 2025 at 8:30 AM ET; includes KOL commentary.","Ongoing POC IITs (3) and Phase 2 studies (2) for crofelemer in MVID and SBS-IF.","Possible expedited regulatory pathways for crofelemer in MVID discussed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-058973","json":"https://secwatch.observer/filing/0000950170-25-058973.json","markdown":"https://secwatch.observer/filing/0000950170-25-058973.md","text":"https://secwatch.observer/filing/0000950170-25-058973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000095017025058973/0000950170-25-058973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000095017025058973/jagx-20250428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:58:20.790641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}